Shares of BioSyent Inc. (CVE:RX - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The company traded as high as C$11.49 and last traded at C$11.48, with a volume of 1179 shares changing hands. The stock had previously closed at C$11.43.
BioSyent Stock Down 2.0 %
The company has a current ratio of 6.13, a quick ratio of 6.91 and a debt-to-equity ratio of 3.19. The business's fifty day moving average price is C$10.92 and its 200 day moving average price is C$10.00. The company has a market capitalization of C$129.81 million, a P/E ratio of 18.67 and a beta of 0.93.
BioSyent (CVE:RX - Get Free Report) last posted its quarterly earnings results on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, hitting the consensus estimate of C$0.13. The firm had revenue of C$8.95 million during the quarter, compared to analyst estimates of C$8.80 million. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. As a group, equities research analysts predict that BioSyent Inc. will post 0.6944444 earnings per share for the current fiscal year.
Insider Buying and Selling
In other BioSyent news, Director Seyed Ahmad Ashrafi sold 2,320 shares of BioSyent stock in a transaction on Friday, September 20th. The stock was sold at an average price of C$10.95, for a total transaction of C$25,404.00. 33.65% of the stock is owned by corporate insiders.
About BioSyent
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Recommended Stories
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
